PubMed · 2020 · 30 citations · 21 references
MedicineEndocrinologyMolecular MedicineApoptosisBone MetabolismOncogenesBone Density RegulationBone HealthBone PhysiologyOsteoblast BiologyOsteoclast BiologyOsteoporosisBone Mineral DensityBone Resorption InhibitionBone Resorption MarkersEstrogen Effects On Bone DensityOsteoclast SurfaceOsteocyte Oxidative StressOsteocyte SenescenceP16 Expression
mRNA expression level. Furthermore, we also demonstrated that p16 deletion inhibited OVX-induced oxidative stress and bone cell senescence, such as a significant decrease in reactive oxygen species levels, up-regulation of superoxide dismutase 1 and 2 protein expression levels, and reduction of the percentage of β-galactosidase-positive osteocytes and p21 protein expression levels in bony tissue. Our results indicate that p16 deletion can prevent estrogen deficiency-induced osteoporosis by inhibiting oxidative stress, osteocyte senescence and osteoclastic bone resorption, stimulating osteogenesis and osteoblastic bone formation. Therefore, this study provides new insights into the potential of p16 as a novel therapeutic target for estrogen deficiency-induced osteoporosis.
21
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Felicia Cosman, Suzanne M. Jan de Beur, Meryl S. LeBoff et al. · Osteoporosis International · 2014 · 4.1K citations · Full text
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Darren J. Baker, Tobias Wijshake, Tamar Tchkonia et al. · Nature · 2011 · 3.6K citations · Full text
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Darren J. Baker, Bennett G. Childs, Matej Durik et al. · Nature · 2016 · 2.8K citations · Full text
Ink4a/Arf expression is a biomarker of aging
Janakiraman Krishnamurthy, Chad Torrice, Matthew R. Ramsey et al. · Journal of Clinical Investigation · 2004 · 1.5K citations · Full text